Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 590

1.

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.

Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K; Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees.

Circulation. 2004 Oct 26;110(17):2618-26. Epub 2004 Oct 18.

PMID:
15492298
[PubMed - indexed for MEDLINE]
Free Article
2.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees.

Lancet. 2003 Sep 6;362(9386):767-71.

PMID:
13678869
[PubMed - indexed for MEDLINE]
3.

Angiotensin inhibition in heart failure.

McMurray JJ.

J Renin Angiotensin Aldosterone Syst. 2004 Sep;5 Suppl 1:S17-22. Review.

PMID:
15526237
[PubMed - indexed for MEDLINE]
4.

[Clinical study of the month. The CHARM study].

Kulbertus H.

Rev Med Liege. 2003 Oct;58(10):646-52. French.

PMID:
14677527
[PubMed - indexed for MEDLINE]
6.

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees.

Lancet. 2003 Sep 6;362(9386):759-66. Erratum in: Lancet. 2009 Nov 21-2009 Nov 27;(9703):1744.

PMID:
13678868
[PubMed - indexed for MEDLINE]
7.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees.

Lancet. 2003 Sep 6;362(9386):772-6.

PMID:
13678870
[PubMed - indexed for MEDLINE]
8.

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.

Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, Olofsson B, Ostergren J, Yusuf S.

J Card Fail. 1999 Sep;5(3):276-82.

PMID:
10496201
[PubMed - indexed for MEDLINE]
9.

ACE inhibitors in heart failure: what more do we need to know?

Demers C, Mody A, Teo KK, McKelvie RS.

Am J Cardiovasc Drugs. 2005;5(6):351-9. Review.

PMID:
16259523
[PubMed - indexed for MEDLINE]
10.

Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.

Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA.

Circulation. 2004 Oct 12;110(15):2180-3. Epub 2004 Oct 4. Erratum in: Circulation. 2005 Jan 25;111(3):378.

PMID:
15466644
[PubMed - indexed for MEDLINE]
Free Article
11.

Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.

Cohen-Solal A, McMurray JJ, Swedberg K, Pfeffer MA, Puu M, Solomon SD, Michelson EL, Yusuf S, Granger CB; CHARM Investigators.

Eur Heart J. 2008 Dec;29(24):3022-8. doi: 10.1093/eurheartj/ehn476. Epub 2008 Nov 5.

PMID:
18987098
[PubMed - indexed for MEDLINE]
Free Article
12.

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.

Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S; CHARM Investigators.

Am Heart J. 2006 Jul;152(1):86-92.

PMID:
16838426
[PubMed - indexed for MEDLINE]
13.

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.

Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Yusuf S.

Am Heart J. 2006 May;151(5):985-91. Erratum in: Am Heart J. 2006 Aug;152(2):354.

PMID:
16644318
[PubMed - indexed for MEDLINE]
14.

Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.

[No authors listed]

Prescrire Int. 2005 Oct;14(79):180-6.

PMID:
16285075
[PubMed - indexed for MEDLINE]
15.

The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.

Pocock S, Wang D, Wilhelmsen L, Hennekens CH.

Am Heart J. 2005 May;149(5):939-43.

PMID:
15894981
[PubMed - indexed for MEDLINE]
16.

Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.

Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA; CHARM Investigators.

J Am Coll Cardiol. 2006 May 16;47(10):1997-2004. Epub 2006 Apr 27.

PMID:
16697316
[PubMed - indexed for MEDLINE]
Free Article
17.

Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.

Cice G, Di Benedetto A, D'Isa S, D'Andrea A, Marcelli D, Gatti E, CalabrĂ² R.

J Am Coll Cardiol. 2010 Nov 16;56(21):1701-8. doi: 10.1016/j.jacc.2010.03.105.

PMID:
21070920
[PubMed - indexed for MEDLINE]
Free Article
18.

Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.

Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators.

Circulation. 2006 Feb 7;113(5):671-8.

PMID:
16461840
[PubMed - indexed for MEDLINE]
Free Article
19.
20.

Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.

Demers C, McMurray JJ, Swedberg K, Pfeffer MA, Granger CB, Olofsson B, McKelvie RS, Ostergren J, Michelson EL, Johansson PA, Wang D, Yusuf S; CHARM Investigators.

JAMA. 2005 Oct 12;294(14):1794-8.

PMID:
16219883
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk